Akinori Hishiya

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona.

MP Healthcare Venture Management, Inc (MP Healthcare Venture) is a venture capital subsidiary of Mitsubishi Tanabe Pharma Corp founded in 2006. The firm is headquartered in Boston, Massachusetts.

QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA.

Mirata Biopharma LLC operates as a pre-clinical stage immuno-oncology company. The firm focuses on developing the next generation of precision immuno-oncology therapeutics. The company was founded in 2017 and is headquartered in Natick, MA.

Diamond Edge Ventures, Inc (Diamond Edge ventures) is a venture capital subsidiary of Mitsubishi Chemical Holdings Corp founded in 2018. The firm is headquartered in San Francisco, California.

Pharmenable Ltd. operates as a drug discovery company. It designs the next generation of small molecule drugs. The company was founded by Hannah Fiona Sore, Natalia Mateu, Jelena Aleksic, David Spring, and Andreas Bender in June 2016 and is headquartered in Histon, the United Kingdom.

Capsigen, Inc. is a company based in Vancouver, WA that is developing the next generation of AAV vectors for gene therapy. The company's end-to-end platform uses customized, diverse libraries and proprietary trade™ technology to identify fully functional vectors that meet disease-specific transduction criteria. Capsigen's fit-for-purpose vectors are designed to deliver the highest level of clinical utility in a rapid and high-throughput manner. The company uses data science and directed evolution to build custom AAV capsids to move patients from hope to cured. John Bial has been the CEO of the company since 2020.